Nomifensine test does not differentiate hyperprolactinemia associated with and without radiologic abnormalities in the sella turcica.
A group of 17 hyperprolactinemic women was given 200 mg of nomifensine orally to evaluate its diagnostic potential to discriminate between tumors and nontumorous hyperprolactinemia. The nomifensine suppressive effect on prolactin serum levels was not significantly different between patients with or without enlargement of the sella turcica. A control group of 5 women with normal prolactin levels exhibited a nomifensine suppressive effect below 65% of the baseline prolactin level, which was significantly different from that in the hyperprolactinemic group. In conclusion it is confirmed that the nomifensine test provides no value in the early diagnosis of the prolactinoma.
D000236:Adenoma / Q000175:diagnosis; D000328:Adult; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000000981:diagnostic imaging / Q000503:physiopathology; D009627:Nomifensine / Q000494:pharmacology; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000378:metabolism; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism; D011859:Radiography; D012658:Sella Turcica / Q000000981:diagnostic imaging* / Q000473:pathology
D009627:Nomifensine; D011388:Prolactin